China has adjusted the tariff lines and rates for 37 medical devices, including surgical robots, in its newly released Import and export tax rules of the PRC (2023).
Sonoscape Medical Corp. obtained marketing approval in China for its intravascular ultrasound (IVUS) diagnostic device and intravascular ultrasound diagnostic catheter.
Zylox-Tonbridge Medical Technology Co. Ltd. has obtained marketing approval for its retrievable inferior vena cava (IVC) filter Zylox Octoplus in China. “Zylox Octoplus is approved for the prevention of pulmonary embolism (PE) and deep vein thrombosis (DVT) in the peripheral vasculature,” a spokesperson at Zylox-Tonbridge told BioWorld. The approval is based on a multi-center, randomized and positive control clinical trial in China. The trial was conducted in nine peripheral vascular intervention centers in China.
Perception Vision Medical Technologies Co. Ltd. (Pvmed) raised around $14 million in a series A financing round, to further develop artificial intelligence (AI) cancer treatment solutions for the two major tumor treatment methods, radiotherapy, and surgery.
Seekin Inc.’s cancer mutation detection kit Pancanseek for leukemia patients has received a CE-IVD mark, expanding the company’s reach in the testing space.
Prenetics Global Ltd. agreed to acquire a majority stake in Act Genomics Holdings Co. Ltd. as part of a move to target the precision oncology market. Prenetics will issue 19.9 million class A ordinary shares and pay $20 million in cash to complete the acquisition.
Medical technology company Synchron Inc. completed an AU$110 million (US$73.9 million) series C round that will allow the company to conduct a feasibility study and pivotal trial of its implantable brain computer interface that can interpret and stimulate parts of the brain.
Gaush Meditech Ltd. raised HK$672 million (US$86.4 million) on a Hong Kong Stock Exchange listing. The company plans to use 38.2% of the funds to improve its research and development capability and speed up the commercialization of its patents in two years.
Chaomu Technology (Beijing) Co. Ltd. has raised nearly ¥100 million (US$14 million) in a series A+ round to develop its ophthalmic medical devices. The proceeds from the financing will be used for the clinical trials of its electromodulation product for nystagmus and the development of implantable medical chips, as well as to speed up the development of products for myopia correction. Following the financing, Beijing-based Chaomu will expand to the global market by looking for collaborations with international institutions. It plans to obtain marketing approvals for its ophthalmic medical devices in the U.S. and Europe.
Chinese authorities this year for the first time allowed access for complete U.S. Public Company Accounting Oversight Board (PCAOB) audit inspections and investigations of PCAOB-registered public accounting firms headquartered in China and Hong Kong, in accordance with U.S. securities law.
RSS
